First Tracks Biotherapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended June 30, 2026, disclosing financials for its first full quarter as an independent public company following a spin-off.

Key Highlights

  • Net loss of $33.4 million for the three months ended June 30, 2026, compared to a net loss of $42.4 million in the same period of 2025, according to the filing.
  • Cash and cash equivalents of $168.0 million as of June 30, 2026, down from $238.2 million at December 31, 2025.
  • Total operating expenses of $34.9 million for Q2 2026, consisting of $25.6 million in research and development and $9.3 million in general and administrative expenses.
  • Spin-off completed in Q2 2026, with the company receiving $100.0 million from its former parent and issuing common stock in connection with the transaction.
  • Public offering raised $75.2 million in gross proceeds, net of $5.3 million in transaction costs, as reported in the filing.
  • 35,730,843 shares outstanding as of August 7, 2026, per the filing's cover page.
  • Basic and diluted net loss per share of $0.95 for the three months ended June 30, 2026, based on a weighted-average share count of 35,003 thousand.

First Tracks Biotherapeutics Reports Q2 2026 Results After Spin-Off Completion

First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a Delaware-incorporated biotherapeutics company headquartered in San Diego, California, filed its Form 10-Q for the quarterly period ended June 30, 2026. The filing reflects the company's first reporting period following its separation from a former parent through a spin-off that was completed during the second quarter of 2026. As part of the spin-off, the company received $100.0 million from its former parent and issued common stock, reclassifying its net former parent investment balance into paid-in capital and common stock.

According to the filing, research and development expenses for the six months ended June 30, 2026 totaled $59.6 million, down from $80.7 million in the same period of 2025. General and administrative expenses for the same six-month period were $28.1 million, compared to $16.4 million in the prior-year period. The company reported a net loss of $83.9 million for the six months ended June 30, 2026, versus a net loss of $89.6 million for the six months ended June 30, 2025. Interest income of $3.9 million partially offset operating losses in the first half of 2026, compared to $7.6 million in the first half of 2025.

The balance sheet as of June 30, 2026 showed total assets of $183.1 million, down from $330.5 million at December 31, 2025, primarily reflecting the drawdown of cash and the elimination of short-term investments, which stood at zero compared to $73.4 million at year-end 2025. Total stockholders' equity was $168.8 million at June 30, 2026. Net cash used in operating activities for the six months ended June 30, 2026 was $64.5 million, while investing activities provided $35.0 million, largely from sales and maturities of investments.

What Was Disclosed

First Tracks Biotherapeutics disclosed its unaudited financial statements for Q2 and the first half of 2026, including balance sheet, income statement, and cash flow data, alongside details of its spin-off from a former parent and a concurrent public equity offering.